NV 1020

Drug Profile

NV 1020

Alternative Names: NV1020; oHSV - MediGene

Latest Information Update: 28 Mar 2016

Price : $50

At a glance

  • Originator MediGene Inc
  • Developer Catherex
  • Class Antineoplastics; Oncolytic viruses
  • Mechanism of Action Apoptosis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Liver cancer

Most Recent Events

  • 17 Mar 2016 Amgen acquires Catherex
  • 13 Apr 2010 Catherex acquires NV 1020 from MediGene Inc.
  • 22 May 2008 Adverse events data from a phase I/II trial in liver metastases presented at the Digestive Disease Week-2008 (DDW-2008)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top